Purepac, Teva Launch Neurontin Generics; Pfizer's Greenstone Unit Follows
This article was originally published in The Pink Sheet Daily
Executive Summary
"At risk" launches of the first AB-rated Neurontin generics by Purepac and Teva are followed by Pfizer's own generic launch through Greenstone.
You may also be interested in...
Pfizer Launches Lyrica Nine Months After First Approval
Pregabalin gestational period encompassed approval of three indications, DEA scheduling and production of packaging.
Pfizer Lyrica Undergoing Controlled Substance Scheduling At DEA
FDA clears pregabalin for management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. The Neurontin follow-on compound remains "approvable" for the adjunctive treatment of partial seizures in adults with epilepsy.
Pfizer Lyrica Undergoing Controlled Substance Scheduling At DEA
FDA clears pregabalin for management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. The Neurontin follow-on compound remains "approvable" for the adjunctive treatment of partial seizures in adults with epilepsy.